Abstract
Objective. To analyze current advances in nanotechnology applications for the development of targeted drugs in oncology, including their mechanisms of action and clinical application prospects.
Material and methods. A comprehensive analysis of scientific literature on nanotechnology applications in anti-cancer drug development was conducted. PubMed, Scopus, and Web of Science databases were used for the period 2000–2024.
Results. The main types of nanoparticles used in oncology, their physicochemical properties, and tumor delivery mechanisms were systematized. The principles of the EPR effect and strategies for improving targeted drug delivery were described. Modern approaches to nanoparticle modification for enhancing their therapeutic efficacy were analyzed.
Conclusion. Nanotechnology represents a promising direction in the development of anti-cancer drugs, enabling improved therapy efficacy and safety. The use of drug delivery nanosystems helps overcome biological barriers and enhance pharmacokinetic parameters of drugs.
Keywords
Authors and affiliations
P.V. Seliverstov(1), A.D. Baksheeva(2), P.S. Koretskaya(3), I.Z. Abdusattarov(4)
1-Federal State Budgetary Educational Institution of Higher Education “S.M. Kirov
Military Medical Academy” of the Ministry of Health of the Russian Federation,
Lebedeva St., 6, Saint Petersburg, 194044, Russian Federation;
2-Peoples' Friendship University of Russia named after Patrice Lumumba,
Miklukho-Maklaya St., 6, Moscow, 117198, Russian Federation;
3-Federal State Autonomous Educational Institution of Higher Education «N.I. Pirogov Russian
National Research Medical University» of the Ministry of Health of the Russian Federation,
Ostrovityanova St., 1, Moscow, 117513, Russian Federation;
4-FSBEI HE “Orenburg State Medical University” Ministry of Healthcare of the Russian Federation,
Orenburg, Sovetskaya St., build. 6, Orenburg Region, 460014, Russian Federation
References
Zhang Y., Li M., Gao X., Chen Y., Liu T. Nanotechnology in cancer diagnosis: progress, challenges and opportunities. J. Hematol. Oncol. 2019; 12 (1): 137. DOI: 10.1186/s13045-019-0833-3
Slamon D., Eiermann W., Robert N., Pienkowski T., Martin M., Press M., Mackey J. et al. Adjuvant trastuzumab in HER2 positive breast cancer. N. Engl. J. Med. 2011; 365 (14): 1273–83. DOI: 10.1056/NEJMoa0910383
Druker B.J., Guilhot F., O'Brien S.G., Gathmann I., Kantarjian H., Gattermann N., Deininger M.W. et al. Five year follow up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 2006; 355 (23): 2408–17. DOI: 10.1056/NEJMoa062867
Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non small cell lung cancer to gefitinib. N. Engl. J. Med. 2004; 350 (21): 2129–39. DOI: 10.1056/NEJMoa040938
Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004; 350 (23): 2335–42. DOI: 10.1056/NEJMoa032691
Ledermann J., Harter P., Gourley C., Friedlander M., Vergote I., Rustin G., Scott C.L. et al. Olaparib maintenance therapy in platinum sensitive relapsed ovarian cancer. N. Engl. J. Med. 2012; 366 (15): 1382–92. DOI: 10.1056/NEJMoa1105535
Barenholz Y. Doxil – the first FDA approved nano drug: lessons learned. J. Control. Release. 2012; 160 (2): 117–34. DOI: 10.1016/j.jconrel.2012.03.020
Gradishar W.J., Tjulandin S., Davidson N., Shaw H., Desai N., Bhar P., Hawkins M. et al. Phase III trial of nanoparticle albumin bound paclitaxel compared with polyethylated castor oil based paclitaxel in women with breast cancer. J. Clin. Oncol. 2005; 23 (31): 7794–803. DOI: 10.1200/JCO.2005.04.937
Michalet X., Pinaud F.F., Bentolila L.A., Tsay J.M., Doose S., Li J.J., Sundaresan G. et al. Quantum dots for live cells, in vivo imaging, and diagnostics. Science. 2005; 307 (5709): 538–44. DOI: 10.1126/science.1104274
Petros R.A., DeSimone J.M. Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov. 2010; 9 (8): 615–27. DOI: 10.1038/nrd2591
Jokerst J.V., Lobovkina T., Zare R.N., Gambhir S.S. Nanoparticle PEGylation for imaging and therapy. Nanomedicine (Lond). 2011; 6 (4): 715–28. DOI: 10.2217/nnm.11.19
Pankhurst Q.A., Connolly J., Jones S.K., Dobson J. Applications of magnetic nanoparticles in biomedicine. J. Phys. D: Appl. Phys. 2003; 36 (13): R167. DOI: 10.1088/0022-3727/36/13/201
Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986; 46 (12): 6387–92.
Hobbs S.K., Monsky W.L., Yuan F., Roberts W.G., Griffith L., Torchilin V.P., Jain R.K. et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. USA. 1998; 95 (8): 4607–12. DOI: 10.1073/pnas.95.8.4607
Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release. 2000; 65 (1–2): 271–84. DOI: 10.1016/s0168-3659(99)00248-5
Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005; 307 (5706): 58–62. DOI: 10.1126/science.1104819
Heldin C.H., Rubin K., Pietras K., Ostman A. High interstitial fluid pressure – an obstacle in cancer therapy. Nat. Rev. Cancer. 2004; 4 (10): 806–13. DOI: 10.1038/nrc1456
Ganta S., Devalapally H., Shahiwala A., Amiji M. A review of stimuli responsive nanocarriers for drug and gene delivery. J. Control. Release. 2008; 126 (3): 187–204. DOI: 10.1016/j.jconrel.2007.12.017
Heitz F., Morris M.C., Divita G. Twenty years of cell penetrating peptides: from molecular mechanisms to therapeutics. Br. J. Pharmacol. 2009; 157 (2): 195–206. DOI: 10.1111/j.1476-5381.2009.00057.x
Bangham A.D., Standish M.M., Watkins J.C. Diffusion of univalent ions across the lamellae of swollen phospholipids. J. Mol. Biol. 1965; 13 (1): 238–52. DOI: 10.1016/S0022-2836(65)80093-6
Drummond D.C., Zignani M., Leroux J.C. Current status of pH sensitive liposomes in drug delivery. Prog. Lipid Res. 2000; 39 (5): 409–60. DOI: 10.1016/s0163-7827(00)00011-4
Gabizon A., Shmeeda H., Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin. Pharmacokinet. 2003; 42 (5): 419–36. DOI: 10.2165/00003088-200342050-00002
Wang-Gillam A., Li C.P., Bodoky G., Dean A., Shan Y.S., Jameson G., Macarulla T. et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine based therapy (NAPOLI-1): a global, randomised, open label, phase 3 trial. Lancet. 2016; 387 (10018): 545–57. DOI: 10.1016/S0140-6736(15)00986-1
Walsh T.J., Finberg R.W., Arndt C., Hiemenz J., Schwartz C., Bodensteiner D., Pappas P. et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N. Engl. J. Med. 1999; 340 (10): 764–71. DOI: 10.1056/NEJM199903113401004
Lancet J.E., Uy G.L., Cortes J.E., Newell L.F., Lin T.L., Ritchie E.K., Stuart R.K. et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J. Clin. Oncol. 2018; 36 (26): 2684–92. DOI: 10.1200/JCO.2017.77.6112
Kim T.Y., Kim D.W., Chung J.Y., Shin S.G., Kim S.C., Heo D.S., Kim N.K. et al. Phase I and pharmacokinetic study of Genexol-PM, a cremophor free, polymeric micelle formulated paclitaxel, in patients with advanced malignancies. Clin. Cancer Res. 2004; 10 (11): 3708–16. DOI: 10.1158/1078-0432.CCR-03-0655
Anderson J.M., Shive M.S. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Deliv. Rev. 2012; 64: 72–82. DOI: 10.1016/j.addr.2012.09.004
. Davis M.E., Zuckerman J.E., Choi C.H.J., Seligson D., Tolcher A., Alabi C.A., Yen Y. et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010; 464 (7291): 1067–70. DOI: 10.1038/nature08956
Boussif O., Lezoualc'h F., Zanta M.A., Mergny M.D., Scherman D., Demeneix B., Behr J.P. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl. Acad. Sci. USA. 1995; 92 (16): 7297–301. DOI: 10.1073/pnas.92.16.7297
Pack D.W., Hoffman A.S., Pun S., Stayton P.S. Design and development of polymers for gene delivery. Nat. Rev. Drug Discov. 2005; 4 (7): 581–93. DOI: 10.1038/nrd1775
Whitehead K.A., Langer R., Anderson D.G. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 2009; 8 (2): 129–38. DOI: 10.1038/nrd2742
Young C., Schluep T., Hwang J., Martin S. CRLX101 (formerly IT-101) – A Novel Nanopharmaceutical of Camptothecin in Clinical Development. Curr. Bioact. Compd. 2011; 7 (1): 8–14. DOI: 10.2174/157340711795163802
Danhier F., Ansorena E., Silva J.M., Coco R., Le Breton A., Préat V. PLGA based nanoparticles: an overview of biomedical applications. J. Control. Release. 2012; 161 (2): 505–22. DOI: 10.1016/j.jconrel.2012.01.043
Huang X., Jain P.K., El-Sayed I.H., El-Sayed M.A. Plasmonic photothermal therapy (PPTT) using gold nanoparticles. Lasers Med. Sci. 2008; 23 (3): 217–28. DOI: 10.1007/s10103-007-0470-x
Toth G.B., Varallyay C.G., Horvath A., Bashir M.R., Choyke P.L., Daldrup-Link H.E., Dosa E. et al. Current and potential imaging applications of ferumoxytol for magnetic resonance imaging. Kidney Int. 2017; 92 (1): 47–66. DOI: 10.1016/j.kint.2016.12.037
Maier-Hauff K., Ulrich F., Nestler D., Niehoff H., Wust P., Thiesen B., Orawa H. et al. Efficacy and safety of intratumoral thermotherapy using magnetic iron oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J. Neurooncol. 2011; 103 (2): 317–24. DOI: 10.1007/s11060-010-0389-0
Khlebtsov N., Dykman L. Biodistribution and toxicity of engineered gold nanoparticles: a review of in vitro and in vivo studies. Chem. Soc. Rev. 2011; 40 (3): 1647–71. DOI: 10.1039/c0cs00018c
Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010; 363 (8): 711–23. DOI: 10.1056/NEJMoa1003466
Kumar A., Zhang X., Liang X.J. Gold nanoparticles: emerging paradigm for targeted drug delivery system. Biotechnol. Adv. 2013; 31 (5): 593–606. DOI: 10.1016/j.biotechadv.2012.10.002
Xie J., Lee S., Chen X. Nanoparticle based theranostic agents. Adv. Drug Deliv. Rev. 2010; 62 (11): 1064–79. DOI: 10.1016/j.addr.2010.07.009
Bonvalot S., Rutkowski P.L., Thariat J., Carrère S., Ducassou A., Sunyach M.P., Agoston P. et al. NBTXR3, a first in class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial. Lancet Oncol. 2019; 20 (8): 1148–59. DOI: 10.1016/S1470-2045(19)30326-2
Wood B.J., Poon R.T., Locklin J.K., Dreher M.R., Ng K.K., Eugeni M., Seidel G. et al. Phase I study of heat deployed liposomal doxorubicin during radiofrequency ablation for hepatic malignancies. J. Vasc. Interv. Radiol. 2012; 23 (2): 248–55. DOI: 10.1016/j.jvir.2011.10.018
Patel N.R., Pattni B.S., Abouzeid A.H., Torchilin V.P. Nanopreparations to overcome multidrug resistance in cancer. Adv. Drug Deliv. Rev. 2013; 65 (13–14): 1748–62. DOI: 10.1016/j.addr.2013.08.004
Riley R.S., Day E.S. Gold nanoparticle mediated photothermal therapy: applications and opportunities for multimodal cancer treatment. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2017; 9 (4): e1449. DOI: 10.1002/wnan.1449
Choi Y.E., Kwak J.W., Park J.W. Nanotechnology for early cancer detection. Sensors (Basel). 2010; 10 (1): 428–55. DOI: 10.3390/s100100428
Wilhelm S., Tavares A.J., Dai Q., Ohta S., Audet J., Dvorak H.F., Chan W.C.W. Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater. 2016; 1: 16014. DOI: 10.1038/natrevmats.2016.14
Ishida T., Kashima S., Kiwada H. The contribution of phagocytic activity of liver macrophages to the accelerated blood clearance (ABC) phenomenon of PEGylated liposomes in rats. J. Control. Release. 2008; 126 (2): 162–5. DOI: 10.1016/j.jconrel.2007.11.009
Kreuter J. Drug delivery to the central nervous system by polymeric nanoparticles: what do we know? Adv. Drug Deliv. Rev. 2014; 71: 2–14. DOI: 10.1016/j.addr.2013.08.008
Resnik D.B., Tinkle S.S. Ethics in nanomedicine. Nanomedicine (Lond). 2007; 2 (3): 345–50. DOI: 10.2217/17435889.2.3.345
Etheridge M.L., Campbell S.A., Erdman A.G., Haynes C.L., Wolf S.M., McCullough J. The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine. 2013; 9 (1): 1–14. DOI: 10.1016/j.nano.2012.05.013